GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
.....or uncannily well-timed buying by insiders at the FDA....LOL. Us PIs don't stand a chance, do we?
I notice that Vectura has also shot up this morning (5%). I wonder if news is leaking out that Hikma / Vectura Advair appeal may go in their favour.
Will go up in my opinion, but �9 was always my target and not greedy. Good luck holders.
Just had a notification from Hikma that final dividend payment date is 24/5/18 (Record date 5/4/18). We won't find out what the actual payment will be until the end of year statement. At least we will be getting a payment due to the fact that Hikma are still profitable.
I think the market is now waiting to see what Hikma is planning to do about the generics situation....I would hope that the market will invest into the proposed turnaround plan ....it is not unusual for the SP to fall, when the market believes a company needs to take decisive action due to market changes
You're right Aamir, the Generic sector at the moment is untenable. No Pharmaceutical company is going to continue selling drugs in this sector without making a decent margin. Products will start to be withdrawn, prices will rise and companies will start to merge with each other. Hikma themselves did state that the Generic market will improve and it will. Fortunately, Hikma don't rely solely on Generics and will be able to ride the storm better than most. Hikma did also state that more resources will be directed to the areas where margins are much better so at least they seem to be addressing the problem. This share is grossly oversold in fact there is a scale that determines how undervalued a company is where 0 is extremely undervalued and 100 is grossly overvalued - - Hikma is currently sitting at 18.
Teva closed six plants last year and plan to close 6 plants this year of generics medicines. I feel similar closure will happen in a sector. If Hikma just sustains in this situation then in near future Generic sector will improve. Or you never know if Democrats come to power in the US then the situation for pharma sector will improve too...
I think Teva poor results Thursday has hit this https://www.cnbc.com/2018/02/08/generic-drugs-giant-teva-warns-on-2018-citing-us-market.html Whilst Hikma is smaller than Teva and more diversified it is clearly going to be continually affected by the generics price erosion. It will be intersting to see what cost cutting measures it will no doubt have to take....
when you buy you suffer an immediate loss of up to �1200-�1500 due to the ridiculous spreads when you guarantee your loss. Thats how they make their money and of course the match you order with them buying the shares as well, so you lose they lose less you win, they win more.
Spreadex
Which platform you use for loaning these stocks?
paper profit son. I dont day trade unless I need to money. I have kept and raised my guaranteed stop loss, so if it tanks I lose a few hundred quid. Company looks way oversold and you only need to DYOR to realise this is a stonking buy at these levels
you made �1500 on a 20p rise but it actually rose 30p from low to high? so you missed out on �750.. i think you sold after a 25p rise and paid 5p per share in costs right?
We have a boaster in our ranks.
well thats was the easiest �1500 in 3 hours....expecting higher rise
Foxykiwi--you will not regret buying at this price and holding long term. The markets do act irrationally at times and they have really excelled themselves on this one.
but this one I missed, but I have taken a long position, having closed my short on Versarien today. Fundementals are too good even if this Advair inhaler drug is delayed or refused. Opened up �75 per point with G/teed stop loss at �8. if I get closed, at least its profit I lost.
Even if they got a takeover bid...so what ? ...sounds like it would be opportunistic and the BOD would turn down the offer...doubt it would even come to the shareholders to vote on... ...If maybe a serious bid came to light, or a bidding war...then maybe....but you dont buy a �2billion company just because you think it is cheap Of course any rumours would boost the SP
Hikma, thankfully has a strong balance sheet and good cash generation. There is no chance of them going out of business (any time soon) which obviously gives me some comfort. It is best for things to play out naturally and the Hikma SP will eventually recover. As long as the dividends are unaffected it will just be like a savings account to me.
Theoratically you right but seems market don't buy this idea. Sometimes if business don't cross breakeven costs thank goes to ground.. Currently this is not the case of Hikma. I have no set no other option but wait for another 3 years... As I am 50% down. I still believe Hikma will winner in longer run in 3 to 5 year's time frame... I will try to forget even I was having any money invested here...
I will repeat what i said a couple of months ago. Nobody can start a pharmaceutical company from scratch and build it up to what Hikma has now for less than £5 Billion and at least 5-10 years hard graft. Hikma is now extremely likely to be subject to a takeover bid and i don't think it will be limited to one suitor.
The MCAP is now �2 billion...the NAV in the 31/12/16 result was �2.4 billion Even if they write down some of the aquisition of Roxane Labs (which seems priced in now) this still looks cheap.... ..but sentiment is very much against it right now
I'm afraid as far as the market is concerned, bad news for Novartis = bad news for Hikma, good news for Novartis = bad news for Hikma. In other words, Hikma can't win.
Hikma's FDA review is due by the end of Q1....they know what the FDA has requested and have also put forward arguing points against FDA decisions....does that make Hikma ahead of the Novartis Generic within the process chain ? I dont think it is possible to equate the two different processes...each follows its own path
Today is five years new low... :(